ethyl 3-[[2-[[4-[(Z)-N'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-4-methyl-1H-benzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate;methanesulfonic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: ethyl 3-[[2-[[4-[(Z)-N'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-4-methyl-1H-benzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate;methanesulfonic acid
• 化学式: C35H45N7O8S
• 分子量: 723.8
• InChiKey: SHWKHLAFBWRVFN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  51
• 可旋转键数：
  17
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  228
• 氢给体数：
  4
• 氢受体数：
  11

文献信息

• [EN] AN IMPROVED PROCESS FOR THE PREPARATION OF DABIGATRAN ETEXILATE MESYLATE<br/>[FR] PROCÉDÉ AMÉLIORÉ DE PRÉPARATION D'ÉTEXILATE-MÉSYLATE DE DABIGATRAN
  申请人：ALEMBIC PHARMACEUTICALS LTD

  公开号：WO2014020555A2

  公开（公告）日：2014-02-06

  The present invention relates to an improved process for the preparation of 1-methyl-2- [N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]benzimidazol-5-yl- carboxylicacid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide methanesulfonate salt (Dabigatran etexilate mesylate ). Further, the present invention provides a process for purification of Dabigatran etexilate mesylate. Further, the present invention provides provide a process for the preparation of 1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]benzimidazol-5-yl-carboxylicacid-N-(2-pyridyl)-N- (2-ethoxy carbonyl ethyl)-amide of formula (VI) an intermediate of Dabigatran.